) The Structural Biology Program is a new addition to the Cancer Center and resulted from the natural convergence of. 1 The necessity for structural information in cancer research; 2 The recruitment of an expert group of structural biologists and establishment of a Center for Structural Biology at the University of Virginia and; 3 The cancer-focus of many of the scientific interests of these investigators, including the multi-drug resistance P-glycoprotein, the Ras oncogene, the small GTPase, RhoA. and the phosphotyrosine-binding adapter protein, Shc. The overall goal of the Program is to integrate, through interdisciplinary collaborations, structural with functional studies of oncogenesis, metastasis and, ultimately, cancer therapy. Expertise and methodologies available include X-ray crystallography, NMR and EPR spectroscopy, atomic force and cryo-atomic force microscopy, total internal reflectance fluorescence microscopy, laser scanning confocal microscopy, X-ray mapping, energy filtered scanning electron microscopy and electron probe X-ray microanalysis. In the short time since the Program was established (May 1998) we made significant advances in high resolution structure determination of cancer related proteins (small GTPase-FAK), and initiated pilot projects (multi-drug resistance glycoprotein P). The Program also disseminates the value and use of structural methods through a seminar series featuring internationally renowned structural biologists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-11
Application #
6205194
Study Section
Subcommittee G - Education (NCI)
Project Start
1987-07-01
Project End
2004-07-31
Budget Start
Budget End
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Virginia
Department
Type
DUNS #
001910777
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Wang, T Tiffany; Yang, Jun; Zhang, Yong et al. (2018) IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective ?-chain cytokines, decreases leukemic T-cell viability. Leukemia :
Yao, Nengliang; Zhu, Xi; Dow, Alan et al. (2018) An exploratory study of networks constructed using access data from an electronic health record. J Interprof Care :1-8
Kiran, Shashi; Dar, Ashraf; Singh, Samarendra K et al. (2018) The Deubiquitinase USP46 Is Essential for Proliferation and Tumor Growth of HPV-Transformed Cancers. Mol Cell 72:823-835.e5
Conaway, Mark R; Petroni, Gina R (2018) The Impact of Early-Phase Trial Design in the Drug Development Process. Clin Cancer Res :
Szlachta, Karol; Kuscu, Cem; Tufan, Turan et al. (2018) CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. Nat Commun 9:4275
Khalil, Shadi; Delehanty, Lorrie; Grado, Stephen et al. (2018) Iron modulation of erythropoiesis is associated with Scribble-mediated control of the erythropoietin receptor. J Exp Med 215:661-679
Olmez, Inan; Zhang, Ying; Manigat, Laryssa et al. (2018) Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma. Cancer Res 78:4360-4369
Parini, Paolo; Melhuish, Tiffany A; Wotton, David et al. (2018) Overexpression of transforming growth factor ? induced factor homeobox 1 represses NPC1L1 and lowers markers of intestinal cholesterol absorption. Atherosclerosis 275:246-255
Banizs, Anna B; Huang, Tao; Nakamoto, Robert K et al. (2018) Endocytosis Pathways of Endothelial Cell Derived Exosomes. Mol Pharm :
Jia, Deshui; Augert, Arnaud; Kim, Dong-Wook et al. (2018) Crebbp Loss Drives Small Cell Lung Cancer and Increases Sensitivity to HDAC Inhibition. Cancer Discov 8:1422-1437

Showing the most recent 10 out of 539 publications